\ Company News
ASX Linkedin Twitter               

 

Company News

11 April 2018 – New CAVATAK Data at International Oncolytic Virus Conference

21 February 2018 – MSD and Viralytics Announce Acquisition Agreement

5 January 2018 – $29.6 Million Equity Placement to Lepu Medical Group of China

12 December 2017 – Malcolm McColl interviewed on CommSec Executive Series

28 November 2017 – Chairman’s letter to shareholders

22 November 2017 – Results of AGM

22 November 2017 – AGM Presentation

22 November 2017 – Chairman’s address to AGM

13 November 2017 – New Data Presented at SITC Annual Meeting

18 August 2017 – Viralytics Annual Report and Full Year Financial Results

01 August 2017 – The Australian – Interest builds in Viralytics’ cancer treatment

28 June 2017 – Viralytics Newsletter

26 June 2017 – Positive Bio-Marker Data from CANON Study

5 June 2017 – Update on MITCI and KEYNOTE 200 trials at ASCO Ann Meeting

5 April 2017 – CAVATAK® in Combination with YERVOY® Provides Promising Results in Advanced Melanoma from the Phase 1b MITCI clinical study

5 April 2017 – Progress in the CAVATAK® and KEYTRUDA® Combination KEYNOTE-200 clinical trial

4 April 2017 – Promising Results in CAPRA Trial of CAVATAK® in Combination with KEYTRUDA® in Melanoma Patients

9 March 2017 – Edison Report – Cavatak combo data at AACR next month

2 March 2017 – Viralytics to Present New CAVATAK Clinical Data at American Association for Cancer Research Annual Meeting 2017

13 February 2017 – Viralytics Receives $4.3 Million R&D Tax Incentive

23 November 2016 – Results of AGM

23 November 2016 – AGM Presentation

23 November 2016 – Chairman’s address to AGM

22 November 2016 – Viralytics Appoints Clinical Advisory Board

14 November 2016 – Promising Advanced Melanoma Results from KEYTRUDA Combination Trial announced at SITC

10 October 2016 – Viralytics presents at European Society Medical Oncology Congress

CAVATAK YERVOY Promising Results in Advanced Melanoma

Update on CAVATAK KEYTRUDA Combination trials

4 October 2016 – Viralytics presents at Oncolytic Virus Therapeutics Conference

25 August 2016 – Viralytics Annual Report and Full Year Financial Results

28 July 2016 – Viralytics MD Dr Malcolm McColl Interviewed on CommSec Executive Series

10 June 2016 – Edison Report – Three Cavatak/checkpoint combination trials

6 June 2016 – Further Positive Clinical Data Presented at ASCO

3 June 2016 – Viralytics MD Dr Malcolm McColl Interviewed on ABC TV The Business

19 April 2016 – Positive Clinical Data from CAVATAK and YERVOY Combination

19 April 2016 – CAVATAK Anti-Cancer Immune Activity in Tumour Micro-environment

19 April 2016 – Checkpoint Combination active in Preclinical Lung, Melanoma

18 April 2016 – Further CAVATAK™ Trial Data: Abstracts Released at AACR Meeting

17 March 2016 – Viralytics to present Clinical Data at AACR Annual Meeting

15 March 2016 – Positive CAVATAK Clinical Data Presented at 2016 EAU Congress

25 January 2016 – Viralytics Completes $4 Million Share Purchase Plan

14 December 2015 – Share Purchase Plan

14 December 2015 – Viralytics Completes $28 million Placement

9 December 2015  – Viralytics Receives $2.9 Million R&D Tax Incentive

18 November 2015  – Results of AGM Meeting

18 November 2015 – AGM Presentation

18 November 2015 – Chairman’s address to AGM

10 November 2015 – The Australian Clinical update boosts Viralytics

9 November 2015 – Positive CAVATAK Clinical Data Presented at 2015 SITC Annual Meeting

6 November 2015 – Viralytics and Merck Collaborate in Lung and Bladder Cancer

28 September 2015 – Viralytics presents data at European Cancer Congress

(Scientific Posters here)

28 September 2015 – VLA initiates Clinical Trial of CAVATAK and PD-1 Combination

26 August 2015 – Viralytics Annual Report and Full Year Financial Results

29 June 2015 – Viralytics MD Dr Malcolm McColl Interviewed on ABC TV The Business

17 June 2015 – Viralytics Presents CALM and STORM Clinical Trial Results at Oncolytic Virus Therapeutics Conference
(Scientific Posters here)

16 June 2015 – CAVATAK™ Presentations at Oncolytic Virus Therapeutics Conference Reinforce Potential in Bladder Cancer and Melanoma

9 June 2015 – Viralytics to Present Initial Positive Results of Clinical Trial of CAVATAK™ in Bladder Cancer at Oncolytic Virus Conference

2 June 2015 – Positive final results from CAVATAK Phase 2 Melanoma Trial

13 May 2015 – Viralytics to present final CALM Clinical Data at ASCO 2015

9 May 2015 – Good Weekend (The Age and The Sydney Morning Herald) Cold War Against Cancer

21 April 2015 – Viralytics Update on CALM and STORM Clinical Trials at American Association for Cancer Research Annual Meeting

18 Mar 2015 – Viralytics to present CAVATAK clinical data at AACR Annual Meeting

6 Mar 2015 – Bioshares: US Investors take note of Viralytics

27 Jan 2015 – Viralytics commences Clinical Trial of CAVATAK in Bladder Cancer

7 Jan 2015 – Sky Business News – Summer Money Interview with Dr Malcolm McColl
Courtesy of Sky News

19 Dec 2014 – Bioshares: Top Six Stock Picks – 2015

4 Dec 2014 – Commencement of Checkpoint Inhibitor Combination Trial

2 Dec 2014 – Viralytics receives $2.5 Million R&D Tax Incentive

28 Nov 2014  – Bioshares: “Viralytics – An Overlooked Investment Opportunity”

27 Nov 2014  – Results of AGM Meeting

27 Nov 2014  – Managing Director’s Address to AGM

27 Nov 2014  – Chairman’s Address to AGM

17 Nov 2014 – BBY: Initiation of Coverage

14 Nov 2014 – Viralytics Receives UK Approval to Commence Clinical Trial of CAVATAK in Bladder Cancer

7 Nov 2014 – Positive CAVATAKTM Combination Data Presented at 2014 Society for Immunotherapy of Cancer (SITC) Meeting
CAVATAK Immunotherapy Combination Poster

24 Oct 2014 – Bioshares: Viralytics and the Next Wave of Cancer Immunotherapies

21 Oct 2014 – Viralytics to present at Australian Microcap Investment Conference
Viralytics Investor Presentation

30 Sep 2014 – CAVATAKTM Immunotherapy Combination Demonstrates Superior Anti-cancer Activity
CAVATAK Immunotherapy Combination Poster

29 Sep 2014  – Dr Robert Andtbacka receives Best Poster in the Melanoma and other skin tumours category at the 39th European Society for Medical Oncology Congress.

Updated Positive Data from Phase 2 Trial of CAVATAK in Late-Stage Melanoma
Poster – CALM Study: Secondary Endpoints of a Phase II study of a novel oncolytic immunotherapeutic agent, Coxsackievirus A21, delivered intratumorally in patients with advanced malignant melanoma

17 Sep 2014 – Updated CAVATAK Results to be presented at ESMO 2014 Congress
CALM Study Abstract
CAVATAK and Checkpoint Inhibitors Abstract

8 Sep 2014 – Peter Turvey appointed to Viralytics Board

2 Sep 2014 – Channel 7 News Report “Brain Drain”
CAVATAKTM among several technologies featured – commencing at 2’35
Courtesy of Channel 7

27 Aug 2014 – Full Year Financial Results and Operational Highlights

23 July 2014 – Bioshares: 10th Bioshares Biotech Summit Investment Panel Report

17 Jul 2014 – Bell Potter Report: Melanoma therapy development gathering steam

4 Jul 2014 – OzEquities Report: Viralytics Overview and current Phase 2 Clinical Trial promising results

12 Jun 2014 – Channel 7 News Report: Cold Comfort
Courtesy of Channel 7

5 Jun 2014 – Edison Report: Keep CALM and carry on

3 Jun 2014 – Progress in CAVATAK Phase 2 Melanoma Trial

3 Jun 2014 – ASCO Poster: Progress in CAVATAK Phase 2 Melanoma Trial

2 Jun 2014 – NBN News Report: Common cold cancer treatment
Courtesy of NBN

15 May 2014 – CAVATAK Cancer Immunotherapy: Progress in Phase 2 Melanoma Trial

15 Apr 2014 – Edison Report: STORMing start to a transformational year ahead

14 Apr 2014 – CAVATAK activity in lung cancer presented at international oncolytic virus conference

14 Apr 2014 – Poster: CAVATAK activity in lung cancer

10 Apr 2014 – Audio of Dr Andtbacka AACR Conference Presentation on CAVATAK

8 Apr 2014 –AACR Slide Deck entitled CAVATAK™-mediated oncolytic immunotherapy in advanced melanoma patients

8 Apr 2014 – Positive Interim Phase 2 Trial Results for CAVATAK

2 Apr 2014 – Viralytics Corporate Video

25 March 2014 – ABC The Business Report: New Frontiers for Australia’s bio-tech industry (external link)

7 Mar 2014 – Bioshares Report: Viralytics Starts Phase I/II Storm Study With Intravenous Cavatak

6 Mar 2014 – General Meeting CEO Presentation

6 Mar 2014 – Viralytics commences STORM Phase 1/2 Clinical Trial

6 Mar 2014 – Anti-cancer activity of CAVATAK to be presented at prestigious US cancer conference

28 Feb 2014 – Viralytics’ $4.1m Entitlement Offer Closes Fully Subscribed

17 Feb 2014 – Shareholder Newsletter February 2014

31 Jan 2014 – Sky News Business Report: Transformational Capital Raising
Courtesy of Sky News

30 Jan 2014 – Viralytics $27 million transformational capital raising

8 Jan 2014 – Target enrolment achieved in CAVATAK™ USA Phase 2 melanoma trial

27 Nov 2013 – Leading US Oncologist joins Scientific Advisory Board

19 Nov 2013 – Results of AGM Meeting

19 Nov 2013 – Chairman Address to AGM

8 Nov 2013 – Investor & Shareholder Presentation

8 Nov 2013 – Further Strong Progress in CAVATAK phase 2 CALM trial

23 Oct 2013 – Viralytics receives $1.9 million in R&D Tax Incentives

18 Oct 2013 – Annual Report 2013

24 Sep 2013 – Edison Report: CAVATAK Phase II meets primary end point

18 Sep 2013 – Primary Endpoint Achieved in CAVATAK Phase II Melanoma Trial

11 Sep 2013 – MHRA Approval for UK Clinical Trial

28 Aug 2013 – Full Year Financial Results – Year Ending 30 June 2013

12 Aug 2013 – Edison Report: Cancer immunotherapy goes viral

7 Aug 2013 – Viralytics’ Patent Coverage Expanded

5 Aug 2013 – Viralytics trading on US OTCQX Marketplace

23 Jul 2013 – Investor and Shareholder Presentation

19 July 2013 – Poster: Interim CALM results

19 July 2013 – Strong interim results of CAVATAK in Phase 2 Trial

18 Jun 2013 – CAVATAK anticancer activity in bladder cancer model

18 Jun 2013 – Poster: CAVATAKTM synergy with standard therapies in bladder cancer

17 Jun 2013 – CAVATAK presentations at international OV conference

17 Jun 2013 – Poster: Investigation of CAVATAK and Chemotherapy on Lung Cancer

17 Jun 2013 – Poster: Combinatory effects of Docetaxel with CAVATAK

17 Jun 2013 – Poster: CAVATAK: Immune cell interactions and oncolytic activity in Leukemia

4 Jun 2013 – CAVATAK ASCO Poster & CALM Trial Recruitment Milestone Achieved

4 Jun 2013 – Poster: CAVATAK ASCO

16 May 2013 – Progress of CAVATAK Phase II study to be presented at ASCO

1 May 2013 – Shareholder Newsletter


© Viralytics Limited 2018